In celebration of all the milestones reached over the last five years, COMBACTE recently launched its second video. Officially released during the COMBACTE Networking Event during ECCMID 2018 in Madrid, it showcases the solid foundation for conducting high quality multiple multisite international clinical trials in the area of antimicrobial drugs development.
Since the start of COMBACTE in 2013, hundreds of clinical trial sites have taken part in the COMBACTE studies, making possible the enrollment of more than 12,000 patients. Currently, three COMBACTE studies have completed recruitment and/or data collection, and seven are ongoing.
COMBACTE’s network currently includes more than 940 clinical trial sites in 42 European countries, and 740 diagnostic labs in 41 countries, making site selection, trial setup and completion faster.
Our academic and industry partners speak about the importance of COMBACTE. ESCMID President and management board member of COMBACTE-CARE Prof. Dr. Jesús Rodríguez Baño (Hospital Universitario Virgen Macarena, Seville) emphasizes the importance of the private-public partnership, and the vital role of the COMBACTE network in developing new drugs that really address the problem of multi drug resistance. Clinical Operations Director at Da Volterra, and Management board member COMBACTE-NET, Mrs. Marie-Noëlle Bouverne: “COMBACTE was a perfect match because it offered a wide network of clinical sites. It would have been very difficult to conduct such a trial [ANTICIPATE] in so many good sites and so quickly, without the COMBACTE network”.